ABC | Volume 115, Nº1, July 2020

Case Report Passos et al. Pulmonary Thromboembolism in COVID-19 Arq Bras Cardiol. 2020; 115(1):142-145 This is an open-access article distributed under the terms of the Creative Commons Attribution License of COVID-19 and eventual occurrence of pulmonary embolism, even in the absence of evidence of deep venous thrombosis. Further studies are still needed to elucidate the pathophysiological mechanisms of thromboembolic events in COVID-19. Acknowledgements To the healthcare professionals engaged in the defense of life, against the Coronavirus. Paraphrasing Winston Churchill, “never was so much owed by so many to so few.” Author Contributions Conception and design of the research and Analysis and interpretation of the data: Passos HD, Sousa ACS; Data acquisition: Passos HD; Writing of the manuscript and Critical revision of the manuscript for intellectual content: Passos HD, Alves MC, Baumworcel L, Vieira JPC, Garcez JDS, Sousa ACS. Potential Conflict of Interest The authors report no conflict of interest concerning the materials and methods used in this study or the findings specified in this paper. Sources of Funding There was no external funding source for this study. Study Association This study is not associated with any thesis or dissertation. Ethics Approval and Consent to Participate Informed consent was obtained from the participant included in the study. 1. Fauci AS, LaneHC, Redfield RR. Covid-19: navigating the uncharted. NEngl J Med.2020. Mar c26;382(13):1268-9. 2. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, el al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13): 1119-207. 3. Wu Z, McGoogan JM. Characteristics of and importante lessons from the coronavirus disease 19 (COVID-19) outbreak in China: summary of a reporto f 72314 cases from the Chinese Center of Disease Control and Prevention. JAMA. 2020;323(13):1239-42. 4. Cui S, Chen S, Li X, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020 Apr 9. doi: 10.1111/jth.14830. [Epub ahead of print] 5. Madjid M, Sfavi-Maeini P, Solomon SD, Vanderny O. Potencial Effects of Coronaviruses on theCardiovascular System: AReview. JAMACardiol.2020. Mar 27. Doi:10.1001/jamacardio.2020.1286. [Epub ahead of print] 6. Iba T, Nisio MDm Levy JH, Kitamura N, Thachil J. New criteria for sepsis- induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a neionwide survey. BMJ Open, 2017 Sep 27;7(9):e017046. 7. GuoT,FanY,ChenM,WuX,ZhangL,HeT,etal.Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27;e201017 ahead of print 8. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Mar 25;e200950. 9. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol. 2020 Apr 15;S0735-1097(20)35008-7 doi: https://doi.org/10.1016/j. jacc.2020.04.031. 10. Features-ThrombosisandCOVID-19;FAQs forCurrentPractice.Cardiology Magazine 2020; Apr 22. [Cited im 2020 May 10]. Available from: acc. org/latest-in-cardiology/articles/2020/04/17/14/42/thrombosis-and- coronavirus-disease-2019-covid-19-faqs-for-current-practice References 145